Efficacy of Symbicort Turbuhaler 160/4.5 mcg as needed versus Oxis 4.5 mcg as needed and Bricanyl 0.4 mg as needed in adults and adolescents with asthma receiving Symbicort Turbuhaler 160/4.5 mcg twice daily as maintenance treatment. A 12-month, randomised, double-blind, parallel-group, active-controlled, phase IIIB, multi-centre study.

Study identifier:SD-039-0734

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Efficacy of Symbicort Turbuhaler 160/4.5 mcg as needed versus Oxis 4.5 mcg as needed and Bricanyl 0.4 mg as needed in adults and adolescents with asthma receiving Symbicort Turbuhaler 160/4.5 mcg twice daily as maintenance treatment. A 12-month, randomised, double-blind, parallel-group, active-controlled, phase IIIB, multi-centre study.

Medical condition

asthma

Phase

Phase 3

Healthy volunteers

Study drug

Sex

Actual Enrollment

Study type

Interventional

Age

Date

Study Start Date: 01 Apr 2003

Primary Completion Date: -

Study Completion Date: -

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Nov 2013 by AstraZeneca

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions

"There is no result for the study"

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=2139&filename=CSR-SD-039-0734.pdf
Download
CSR-SD-039-0734.pdf
Download
Trial Results Summaries
Available here

Official Title

Medical condition

Phase

Healthy volunteers

Study drug

Sex

Actual Enrollment

Study type

Age

Date

Study design

Verification:

Sponsors

Collaborators

Inclusion Criteria

Exclusion Criteria

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=2139&filename=CSR-SD-039-0734.pdf

CSR-SD-039-0734.pdf

Trial Results Summaries